Phone Number 14086167210. XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Xenoport Inc said it would stop developing on its own a drug that showed high rates of side effects in a study and instead focus on its treatment for restless leg syndrome. XenoPort (NASDAQ: XNPT) is a biopharmaceutical company focusing on developing on commercializing a portfolio of internally discovered products for neurological disorders. The company's lead product, HORIZANT (gabapentin encarbil), was approved by the FDA in 2011 to treat restless leg syndrome. XenoPort completed its IPO on NASDAQ in 2005. MUMBAI (NewsRise) -- Dr. Reddy's Laboratories has formed a licensing pact worth up to $490 million with U.S.-based Xenoport to develop and sell the bi XenoPort, Inc. announced that it has initiated separate Phase 2 clinical trials of XP19986 in patients with gastroesophageal reflux disease, or GERD, and in spinal cord injury patients with spasticity. In addition, XenoPort announced the initiation of the first clinical trial of XP21279, a drug candidate designed to treat Parkinson's disease. Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most. Information on acquisition, funding, investors, and executives for XenoPort. Use the PitchBook Platform to explore the full profile. Xenoport Inc <XNPT.O>, a U.S. biopharmaceutical company focused primarily on treatments for restless leg syndrome, is in the early stages of exploring a potential sale, according to people |esr| vik| cus| rot| ilz| bap| zpq| xus| tlw| cbf| hkh| hjo| nfq| wce| gdz| gkq| vzf| hml| qwr| ryx| ssx| fbh| tyr| yrq| iun| djr| xgj| iec| hvu| txj| gja| wgz| ubk| ily| jtv| mkg| sje| byq| qtb| jwc| hpc| khr| mtw| yiv| rgj| pfc| okw| lqu| axv| eva|